MD-IPROOV
Mvine and iProov announce today their design for a simple, secure and widely recognized Covid-19 immunity and vaccination passport will now move into live testing. The Mvine-iProov passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure.
With additional backing from Innovate UK, which initially funded the development of a successful working prototype, the Mvine-iProov passport will now be tested by Directors of Public Health within the National Health Service (NHS) in the UK. Mvine and iProov aim to complete two trials by 31 March 2021, giving Directors of Public Health across the country the confidence to deploy the passport at scale to benefit their local areas.
Crucially, the Mvine-iProov passport can be plugged into the NHS’ existing infrastructure, enabling it to meet the specific needs of local Directors of Public Health and any overarching national requirements. This flexibility ensures that areas in different tiers or levels of vaccination rollout can set appropriate policies and enforce them with confidence.
The Mvine-iProov passport has been developed quickly and cost-efficiently, with a total £75,000 investment from Innovate UK following a call for ideas in April 2020. It is expected this investment in UK innovation will help businesses and employees return to work, and enable families and friends to reconnect, more quickly and more responsibly than would otherwise be possible.
Frank Joshi, Director at Mvine, said: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy. Unlike some other digital solutions for Covid-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead .”
Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three. Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”
ENDS
About iProov
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to remotely verify customer identity. Used for onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), GovTech Singapore, Eurostar, Rabobank, ING, and others. iProov’s unique patented technology provides Genuine Presence Assurance, ensuring that an online customer is the right person, a real person, and authenticating right now. This protects against spoof attacks from photos, videos, masks and the emerging threat of deepfakes. iProov was recognized as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50 and was also named a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com
About Mvine
Mvine Limited is a British deep tech company delivering next generation platforms that power the digital economy. It is perhaps best known for its work in providing cyber-secure collaboration portals, in use in the financial services sector as virtual deal rooms and in other industries as procurement portals and as diversity/equality portals. The company has also pursued identity management and its technology is in use in the telecoms sector for federated authentication and in other industries for single sign on identity, authentication and authorization. www.mvine.com
About Innovate UK
Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org
Fact Checking
The UK government announcement on 20 May 2020 to expand the funding envelope from £20 million to £40 million meant 800 funding awards could be made. The original announcement was made on 3 April 2020 by BEIS, Innovate UK and Amanda Solloway MP. The competition opened Friday 3 April 2020 and closed Friday 17 April 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112006124/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom